Clinical trials: CD7+ T-ALL/LBL
Neoplasms, Hematologic Neoplasms
RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL, and to evaluate the…
- Conditions
- Neoplasms, Hematologic Neoplasms, Hematologic Diseases
- Trial name
- NCT05902845
- Testing
- RD13-02 cell infusion
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Xiaoyu Zhu
T Lymphoblastic Leukemia/Lymphoma
Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.
To Evaluate the Efficacy and safety of S101 for Treating CD7-Positive Relapsed or Refractory T-LBL/ALL.
- Trial name
- NCT07244380
- Testing
- Autologous CD7-targeting CAR T cells
- Volunteers
- 38 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
T-cell Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma
A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL
T cells are a type of immune cell. Like other cells of the body, T Cells can develop cancer. T cell cancers mainly include T cell leukaemia and T cell lymphoma, both of which have a relatively poor prognosis.
- Trial name
- NCT04860817
- Testing
- Target CD7 CAR-T cells
- Where
- China
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
T-cell Acute Lymphoblastic Leukemia/Lymphoma
Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells
This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD7 CAR-T cell in the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (TLBL).
- Trial name
- NCT04572308
- Testing
- CD7 CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Neoplasms, Hematologic Neoplasms
CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL, and to evaluate the…
- Conditions
- Neoplasms, Hematologic Neoplasms, Neoplasms by Site, Hematologic Diseases
- Trial name
- NCT05716113
- Testing
- RD13-02 cell infusion
- Where
- China
- Volunteers
- 20 people
- Sponsor
- He Huang
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
This study will provide long-term follow-up for patients who have received treatment with WU-CART-007 in a previous clinical trial.
- Trial name
- NCT05509855
- Testing
- Genetic: WU-CART-007
- Where
- 5 sites in United States, Australia
- Volunteers
- 44 people
- Sponsor
- Allotera Therapeutics
CD7+ T-ALL/LBL
Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
This is a phase I, open-label, dose-escalation clinical trial. The primary objectives are to assess the safety of PA3-17 injection in pediatric and adolescent participants with relapsed/refractory T-lymphoblastic…
- Trial name
- R/R T-ALL/LBL (NCT07623681)
- Testing
- T cell injection targeting CD7 chimeric antigen receptor
- Where
- China
- Volunteers
- 12 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
T Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma
RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL
This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed and/or refractory T cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
- Trial name
- NCT04620655
- Testing
- RD13-01 cell infusion
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Min Xiang
Hematological Malignancies
CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies
This is a open-label, phase 2 study to evaluate the efficacy, safety and PK of CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7 positive hematological malignancies.
- Trial name
- NCT05454241
- Testing
- Anti-CD7 CAR-T
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
T-ALL, Lymphoma, T-Cell
SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies
To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory CD7+ hematolymphoid malignancies.
- Trial name
- NCT05398614
- Testing
- SENL101
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
T Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia (AML)
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
The aim of this study was to evaluate the safety and efficacy of supCD7 CART cells in the treatment of patients with relapsed/refractory CD7-positive hematologic malignancies.
- Trial name
- NCT07153068
- Testing
- supCD7 CART cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia (AML), T Lymphoblastic Leukemia/Lymphoma
uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
The aim of this study was to evaluate the safety and efficacy of universal CD7 CART (uCD7 CART) cells in the treatment of patients with relapsed/refractory CD7-positive hematologic malignancies.
- Trial name
- NCT07109518
- Testing
- uCD7 CART
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Neoplasms, Hematologic Neoplasms
Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL/AML, and to evaluate the…
- Conditions
- Neoplasms, Hematologic Neoplasms, Hematologic Diseases
- Trial name
- NCT05907603
- Testing
- RD13-02 cell infusion
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Kai Lin Xu，MD
T-lymphoblastic Lymphoma, T-ALL
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.
- Trial name
- NCT06136364
- Testing
- CAR-T
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
T Lymphoblastic Lymphoma, T Acute Lymphoblastic Leukemia
Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL
This study is an open, single-center, prospective clinical trial, with newly diagnosed high-risk T-LBL/ALL patients as the subjects. It plans to enroll 10 subjects.
- Trial name
- NCT07476027
- Testing
- CD7 CAR-T cell intravenous infusion
- Volunteers
- 10 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
The purpose of this study is to evaluate the safety, recommended dose, and preliminary anti-tumor activity of WU-CART-007 in patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic…
- Trial name
- NCT04984356
- Testing
- WU-CART-007
- Where
- 12 sites in United States, Australia and 2 more
- Volunteers
- 28 people
- Sponsor
- Allotera Therapeutics
T-cell Acute Lymphoblastic Leukemia/Lymphoma
Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL
This is an open, prospective, dose-escalation clinical study to evaluate the safety and efficacy of Senl-T7 in patients with relapsed or refractory CD7+ acute T lymphoblastic leukemia or T lymphoblastic lymphoma.Meanwhile, PK/PD…
- Trial name
- NCT05626400
- Testing
- Senl-T7
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Leukemia, T Cell
Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia
This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD7 CAR-T cell in the treatment of CD7 Positive acute leukemia or mixed lineage leukemia except those who are diagnosed with T-ALL/T-LBL
- Trial name
- NCT04938115
- Testing
- CD7 CART
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
CD7+ T-ALL/LBL
To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
To observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of T-lymphoblastic leukaemia/lymphoma with postive measurable residual disease positive post allogeneic stem cell…
- Trial name
- S101MRD (NCT07280494)
- Testing
- CAR-T Therapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking University People's Hospital